Effect of β2-agonist treatment on insulin-stimulated peripheral glucose disposal in healthy men in a randomised placebo-controlled trial
Open Access
- 12 January 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-15
Abstract
β2-agonist treatment improves skeletal muscle glucose uptake and whole-body glucose homeostasis in rodents, likely via mTORC2-mediated signalling. However, human data on this topic is virtually absent. We here investigate the effects of two-weeks treatment with the β2-agonist clenbuterol (40 µg/day) on glucose control as well as energy- and substrate metabolism in healthy young men (age: 18-30 years, BMI: 20-25 kg/m2) in a randomised, placebo-controlled, double-blinded, cross-over study (ClinicalTrials.gov-identifier: NCT03800290). Randomisation occurred by controlled randomisation and the final allocation sequence was seven (period 1: clenbuterol, period 2: placebo) to four (period 1: placebo, period 2: clenbuterol). The primary and secondary outcome were peripheral insulin-stimulated glucose disposal and skeletal muscle GLUT4 translocation, respectively. Primary analyses were performed on eleven participants. No serious adverse events were reported. The study was performed at Maastricht University, Maastricht, The Netherlands, between August 2019 and April 2021. Clenbuterol treatment improved peripheral insulin-stimulated glucose disposal by 13% (46.6 ± 3.5 versus 41.2 ± 2.7 µmol/kg/min, p = 0.032), whereas skeletal muscle GLUT4 translocation assessed in overnight fasted muscle biopsies remained unaffected. These results highlight the potential of β2-agonist treatment in improving skeletal muscle glucose uptake and underscore the therapeutic value of this pathway for the treatment of type 2 diabetes. However, given the well-known (cardiovascular) side-effects of systemic β2-agonist treatment, further exploration on the underlying mechanisms is needed to identify viable therapeutic targets.Keywords
Funding Information
- Nutrim NWO graduate program
- ZonMw
- ZonMW and the Dutch Diabetes foundation
This publication has 45 references indexed in Scilit:
- Branched-Chain and Aromatic Amino Acids Are Predictors of Insulin Resistance in Young AdultsDiabetes Care, 2013
- Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of AktAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Prolonged Fasting Identifies Skeletal Muscle Mitochondrial Dysfunction as Consequence Rather Than Cause of Human Insulin ResistanceDiabetes, 2010
- A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin ResistanceCell Metabolism, 2009
- Characterization of the β‐adrenoceptor subtype involved in mediation of glucose transport in L6 cellsBritish Journal of Pharmacology, 2002
- Attenuation of insulin resistance by chronic β2-adrenergic agonist treatment Possible muscle specific contributionsLife Sciences, 2001
- Effects of Therapeutic Doses of Albuterol on β2-Adrenergic Receptor Density and Metabolic ChangesJournal of Asthma, 2001
- The lipolytic effect of beta 1‐ and beta 2‐adrenoceptor activation in healthy human volunteers.British Journal of Clinical Pharmacology, 1993
- Modulation of lipoprotein lipase activity in the rat by the β2-adrenergic agonist clenbuterolCanadian Journal of Physiology and Pharmacology, 1992
- EXPERIENCES OF LONGTERM TREATMENT OF ASTHMA WITH TERBUTALINE*Allergy, 1971